Glenmark Study Shows Favipiravir Provides Significant Benefits In COVID-19 Treatment

Mumbai, 23 Nov 2020:

Drug firm Glenmark Pharmaceuticals said that as per recently published data, the oral antiviral medication favipiravir was found to provide significant benefits in COVID-19 treatment including faster time to clinical cure.

These findings were observed in a randomized, controlled phase 3 clinical study conducted by the company and the results are now published online in The International Journal of InfectiousDiseases (IJID).

The phase 3 study with antiviral drug favipiravir, brand name FabiFlu, was conducted in 150 patients as part of a randomised, open label, multicenter, phase 3 study.

The study aimed to evaluate the efficacy and safety of favipiravir plus standard supportive care (favipiravir treatment arm), versus standard supportive care alone (control arm), in mild to moderate patients, randomized within a 48 hour window of testing RT-PCR positive for COVID-19.

Favipiravir was found to provide multiple treatment benefits, demonstrated by faster time to clinical cure, and significantly delayed the need for supportive oxygen therapy, the company said.

Robert Crockart, chief commercial officer, Glenmark Pharmaceuticals said, “From the first reported case of COVID-19, our every effort was to bring a viable, safe and effective treatment option to patients in a timely manner. It is encouraging to see our trial results now published in a reputed global medical journal, which we hope will support other countries in their fight against this disease.”Pharmabiz